Olmesartan comes through for Daiichi Sankyo
This article was originally published in Scrip
Sales and profits at Daiichi Sankyo came in ahead of the company's own forecasts for the first half to September 30th, helped by strong US sales, non-operating gains from the valuation of Ranbaxy's foreign exchange derivatives and the one-off sale of investment securities.
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.